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Introduction: The Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA) acknowledge in their guidelines that diabetic care is complex and requires 
that numerous issues, beyond glycaemic control, be addressed. To further ensure a high 
quality of care, it is necessary that healthcare workers constantly check whether the 
standard of care offered is effective, equitable, efficient and humane. 
Aim: The aim of the study was to review the clinical management of patients with type 
2 diabetes at Leratong Hospital in relation to the SEMDSA guidelines for Diagnosis and 
Management of Type 2 Diabetes Mellitus for Primary Health Care – 2009.  
Methods: This was a observational descriptive study using data from the charts of 388 
patients with type 2 diabetes who access care at Leratong Hospital.  
Results: The majority of participants were male. Their average age was 55.7 years 
(range: 33 to 83 years). The glycosylated haemoglobin was documented in 64.95% of 
patients, weight in 5.67%, blood pressure in 96.39%, lipid in 21.39%, serum creatinine 
in 90.46%, urine dipstick in 90.91%, patient education in 98.2%, eye examination in 
51.8%, foot examination and micro albumin in less than 1%. Optimal control of 
glycosylated haemoglobin, systolic blood pressure, diastolic blood pressure, cholesterol 
and triglyceride was noted in 5.56%, 46.72%, 16.8%, 80.77% and 74.67% respectively. 
Thirty eight percent of patients were on two oral anti diabetic agents, the majority of 
patients (94.32%) were receiving an ACE inhibitor for blood pressure control, 34.02% 




Conclusion: overall the quality of management of patients with type 2 diabetes is poor 
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ACE Inhibitor: Angiotensin Converting Enzyme Inhibitor  
ADA: American Diabetes Association  
AntiHPT: Antihypertensive  
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Chapter 1 INTRODUCTION 
1. Introduction 
The diabetic pandemic is growing worldwide and is a large contributor to the increasing 
incidence of chronic disease, particularly in developing countries1. In 2010, there were 
an estimated 285 million patients with diabetes mellitus worldwide, and this number is 
expected to increase to 438 million by the year 2030.2 The number of adults with 
diabetes in sub-Saharan Africa is expected to expand by 98% from 12.1 million in 2010 
to 23.9 million in 2030. An exact number is not available due to many people that are 
undiagnosed and living with type 2 diabetes. Another contributing factor is the paucity 
of data in Africa3 
 
Type 2 diabetes commonly occurs among people over the age of 40 years, although 
with the increase in obesity it is now not uncommon to diagnose type 2 diabetes in 
patients under 40 years of age. Africa has not escaped the disease with a prevalence of 
diabetes of 3.8% compared to the global prevalence of diabetes of 6.4%.2   
Type 2 diabetes is as result of a number of factors including genetics, unhealthy diet and 
lack of physical activity. Type 2 diabetes can be effectively controlled by a number of 
interventions such as lifestyle modification, oral diabetic medication and the use of 
insulin when oral medication is no longer effective.4 Failure to adequately manage 
diabetes can result in macrovascular and microvascular complications, and can result in 
avoidable deaths.  Effective management of diabetes mellitus requires ongoing 
collaboration between the patient and the health care team. Evidence based guidelines 
developed by the Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA) for the diagnosis and management of Type 2 diabetes mellitus in primary 
health care are available for health care workers in South Africa.4 The patient needs to 
be encouraged to give attention to lifestyle issues (exercise, weight loss, diet etc), 
adherence to medication and, as the disease progresses, the use of insulin. The health 
care team must be knowledgeable about the disease, its treatment and the need for 
ongoing monitoring to ensure that any complications arising from the disease are 
identified early and managed effectively.  Correct management of the condition will 
help minimize the development of complications and (hopefully) ensure a long and 






Type 2 diabetes is the most common form of diabetes accounting for around 90% of all 
diabetics in sub-Saharan Africa, similar to other regions of the world.3 
From 1990 to 2000 the prevalence of diabetes mellitus in Africa increased by 30%.5 
Within South Africa, studies show that an estimated 2 to 3 million people are affected 
by diabetes, with the number rising annually.5Of these, up to 1 million people may not 
even know that they are diabetic.5 This is a common problem in Africa, where many 
diabetic patients remain undiagnosed, with figures ranging from 80% in Cameroon to 
55% in Cape Town. 6, 7 These numbers are mainly made up of patients with type 2 
diabetes with the increase in prevalence of diabetes thought to be mainly related to 
lifestyle changes and increased obesity.5 
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes estimate that 
6,5% of adults between the age of 20 and 79 years old have diabetes.8  
Within South Africa, the prevalence of diabetes is higher in urban areas than it is in 
rural areas.6,7 The rising prevalence of impaired glucose tolerance is a warning sign is 
due mainly to increasing obesity and decreased physical activity.6,7 As type 2 diabetes is 
occurring in younger people, there are an increasing number of complications due to the 
disease such as  blindness, amputations and kidney  problems.  These complications will 
have economic consequences both for the individual and for the country.9 
Due to its complications, diabetes is associated with significant morbidity and 
mortality.9Complications such as heart disease, stroke, amputation, blindness, kidney 
failure, cardiovascular disease and hypertension, all of which occur more commonly 
among diabetic patients lead to a decreased life expectancy.9  The World Health 
Organization (WHO) reports that diabetes mellitus is the fourth largest underlying cause 
of death globally.9,10 It is therefore very important that diabetic patients receive ongoing 
high quality care and treatment.7,10 
Public health services in South Africa are faced with a shortage of doctors and other 
health care professionals, which has impacted negatively on the quality of care provided 
to patients.11Patients often queue from early in the morning to be seen by a health care 
professional and to receive their monthly treatment.  Access to public health facilities 
can be a problem for those with limited income, who live far away or have family 
responsibilities that prevent them from keeping their regular appointments.  Poverty and 
unemployment affect many people who attend these services, and their health status 




3. Problem statement 
The effectiveness of the current management and care practices of  type 2 diabetes 
patients at Leratong Hospital is unknown. Based on the profile of patients seen in 
casualty there is also concern about whether the guidelines, as prescribed by the clinical 
manager, are being adhered to. 
 
4. Aims and objectives 
The aim of this study was to review the management of patients with Type 2 diabetes 
mellitus in relation to guidelines for diagnosis and management of diabetes mellitus for 
primary care produced by the Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA) at Leratong Hospital in Gauteng. 
Objectives: 
i. To review the demographic profile of patients with type 2 diabetes 
mellitus presenting for care to Leratong Hospital. 
ii. To review whether processes of care (such as HbA1c, lipid profile, blood 
pressure, eye examination, weight and BMI) are carried out each month.  
iii. To review the metabolic outcome of patients with Type 2 diabetes 
mellitus (HbA1C, blood pressure and lipid profile).  
iv. To review the pharmacological management of patients with Type 2 
diabetes mellitus in relation to their diabetic (and related) diseases.  
v. To provide recommendations to the hospital manager about ways of  
improving the care of patients with type 2 diabetes mellitus. 
 
5. Definitions 
There are many definitions which could be used to define quality of care. However for 
the purposes of this study I have chosen to use the Institute of Medicine definition 
which has defined quality of care as ‘the degree to which health services for individuals 
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and populations increase the likelihood of the desired health outcomes and are 
consistent with current professional knowledge’.12 
Furthermore, targets for care consist of two elements: process and outcome measures. 
Process measures refer to what is actually done and outcome measures comprise the 
final stage in the structure-process-outcome paradigm. The criteria for evaluating 
appropriateness typically relates to whether the proposed intervention in a specific 
clinical setting is consistent with scientific evidence and accepted 
practice.12Theoretically, high quality of care should lead to better outcomes and regular 
outcome assessment is critical to the evaluation of the quality of care.12 
 
6. Significance of study 
There is minimal information available on whether the SEMDSA guidelines for diabetic 
care are being implemented at state-funded clinics and hospitals in South Africa and this 




Chapter 2  LITERATURE REVIEW 
1. Introduction 
This chapter will present the signs and symptoms of diabetes mellitus, specifically type 
2 diabetes and will review the treatment options available.   This will include blood 
pressure management, lipid treatment and antiplatelet agents.  This will be followed by 
a review of international management guidelines to ensure that patients receive the best 
quality of care. 
2. Types 2 Diabetes 
The most common factor used to diagnose Type 2 diabetes is hyperglycaemia, which is 
caused by insulin resistance and / or  impaired insulin secretion.13 Patients who present 
with symptoms of hyperglycaemia and a blood sugar reading greater to or equal to 
11.1mmol/l or two blood sugar readings greater than 11.1 mmol/l are diagnosed with 
diabetes mellitus.4Long-term diabetes can cause macro and micro vascular 
disease.7,11 Diabetic micro vascular disease leads to significant morbidity in the form of 
blindness, end-stage renal disease and limb amputations.9,13 Diabetic macro vascular 
disease is characterised by accelerated atherosclerosis, which leads to peripheral 
gangrene, strokes and premature cardiovascular disease.9,13 
Beside hyperglycaemia and insulin resistance, over 80% of diabetics are obese and have 
a host of metabolic abnormalities. These include  dyslipidaemia (characterised by an 
increase in small dense low density lipoprotein (LDL) cholesterol, a decrease high 
density lipoprotein (HDL) cholesterol, and an increase in triglyceride levels) as well as 
hypertension. These contribute to the higher incidence of cardiovascular morbidity and 
mortality which is seen amongst diabetic patients.13 
3. Diabetes Care 
In a patient with established diabetes, it is very important to perform a complete medical 
evaluation in order to classify the diabetes, detect the presence of diabetic 
complications, review the previous management of diabetes and assist in formulating a 
management plan, which will be the basis for continuing care.9 It is also important to 
educate the patient on all aspects of the disease, as he / she will be a life-long ‘partner’ 
in the management of his / her diabetes.13  Ideally, all patients with diabetes should 
receive medical care from a physician-coordinated team9 A management plan should be 
drawn up and  formulated as a mutual therapeutic alliance between the patient and 
his/her family, the physician, and other members of the health care team.9  To carry out 
the management plan, each aspect of the plan needs to be  understood and agreed on by 
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the patient and his team, and the goals laid out by the treatment plan  must be 
attainable.9 
SEMDSA, among many other professional organisations, published an algorithm for the 
glycaemic management of patients with type 2 diabetes in 2009.4  Diabetes care is 
complex and requires that many issues, beyond glycaemic control, be addressed 
9  Quality care of the diabetic patient requires particular attention to blood pressure 
control, management of dyslipidaemia, reduction in associated cardiovascular risk 
factors, screening for complications of diabetes and assisting patients in their pursuit of 
an improved quality of life.9,14  Dyslipidaemia and blood pressure are clear risks for 
cardiovascular disease in patients with type 2 diabetes and should be treated more 
aggressively in patients with type 2 diabetes because of increased risk of both macro 
and micro vascular complications.9 
To achieve high quality of diabetes care, diabetics clinics must be well organised with 
well trained and dedicated staff in diabetes care that use effective protocols and 
appropriate tools. A process of regular audit with the implementation of interventions to 
improve care needs to be instituted.8  
Blood pressure management 
Blood pressure should be measured at every routine visit and treatment should be 
instituted if the blood pressure is found to be high.4,9 Diabetic patient with a systolic 
blood pressure (SBP) greater than 130mmHg or diastolic blood pressure (DBP) greater 
80mmHg should have their blood pressure confirmed on a separate day. A repeat SBP 
of 130 mmHg or greater, or DBP of 80mmHg or greater confirms a diagnosis of 
hypertension.4, 9 A goal of less than 130mmHg and 80 mmHg for SBP and DBP 
respectively is recommended by the SEMDSA guidelines.4,9 
Lifestyle modification should be instituted at diagnosis of hypertension in all diabetic 
patients. If these measures fail to adequately control the blood pressure, 
pharmacological therapy should be added to life style modification.4, 9 Lifestyle 
modification for hypertension consists of: weight loss, if overweight;  the DASH 
(Dietary Approaches to Stop Hypertension) diet which includes reducing sodium and 
increasing potassium intake; ensuring that alcohol is only taken in moderation; and 
ensuring that patients exercise regularly.4, 9As regular physical activity helps to maintain 
weight loss and prevent weight regain, 30-45 minutes of moderate-intensity aerobic 
physical activity (3-5 days per week initially, gradually increasing the duration and 
frequency) is recommended.4 
The drug of choice for diabetic patients with hypertension is an angiotensin converting 
enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) in case of intolerance 
to the former. In black patients, low dose thiazide is preferable as initial therapy.4,9 
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Multiple drug therapy (two or more agents at maximal doses) are often  required to 
achieve blood pressure targets4,9 
Lipid management            
Lipids should be measured annually or even more frequently if they are high and after 
the initiation of treatment.16 
Lipid therapy is implemented in order to gain or maintain reasonable levels of LDL-
cholesterol. The SEMDSA guidelines for the management of patients with Type 2 
diabetes set the target control for the total-cholesterol at < 4.5mmol/l, LDL-cholesterol 
at < 2.5mmol/l (or less than1.8 mmol/l in the presence of ischaemic heart disease, 
cerebrovascular disease or peripheral vascular disease), HDL- cholesterol >1.0mmol/l 
(men) and >1.2mmol/l (women) and less than 1.7mmol/l for triglycerides.16 
Dyslipidaemia is also managed by lifestyle modification. The reduction of saturated fat, 
trans fat, and cholesterol intake; increase of omega-3, fatty acids, viscous fibre, and 
plant stanols/sterol; weight loss (if indicated); and increased physical activity should be 
recommended to improve the lipid profile in patients with diabetes.4 
Statins are first line agents for lowering LDL-cholesterol in diabetic patients and in 
accordance with this, statin therapy should be added to lifestyle therapy, regardless of 
baseline lipid levels for all patients with type 2 diabetes with existing cardiovascular 
disease or patients older than 40 years of age and who have one or more additional 
cardiovascular risk factors.4, 16For diabetic patients at lower risk (without established 
cardiovascular disease or under 40 years of age), statin therapy should be considered if 
the LDL-cholesterol remain > 2.5mmo/l despite adequate glycaemic control and advice 
on lifestyle.4, 16 The addition of fibrate or another lipid modifying drug may be 
necessary in certain specific condition.4, 16 
Antiplatelet agent 
Aspirin is indicated for primary or secondary prevention of cardiovascular problems in 
patients with type 2 diabetes with increased or established cardiovascular risk factors for 
patients over 30 years of age.4,9 In cases where the patient is allergic to aspirin, 
clopidogrel can be used.4,9 
Improving the quality of care 
In order to ensure the proper management of diabetic patients and that high standards of 
care are achieved,  guidelines targeting (among many others) primary care providers, 
have been published by professional organizations such as the Canadian Diabetes 
Association5, the American Diabetes Association9, the World Health Organization8 and 
in South Africa, the Society for Endocrinology, Metabolism and Diabetes of South 
Africa (SEMDSA).4  When primary care physicians follow these guidelines they  play an 
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important role in helping patients with type 2 diabetes to achieve therapy 
goals.10 Unfortunately, many published South African studies show that that the quality 
of diabetic care received by patients in the public sector hospitals and clinics is 
inadequate and by in large the guidelines are not followed. 13, 15 
Much evidence exists supporting a range of interventions to improve diabetes 
outcomes.14 Clinical audit is an accepted and popular method of assessing medical care 
and is an intervention shown to improve patient care.14 It is defined by Marshall 
Marinker as 'the attempt to improve the quality of medical care by measuring the 
performance of those providing that care, by considering the performance in relation to 
desired standard and by improving on this performance’.14 
A clinical audit brings together professionals from all sectors of health care to consider 
clinical evidence, promote education and research, develop and implement clinical 
guidelines, improve information management skills, and contribute to the better 
management of resources—all with the aim of improving the quality of care of 
patients.16 
Clinical audit is an important tool which should be used regularly, not only for the 
Family Physician, but for all health care workers in order to improve the quality of care 
of their patients.  Done repeatedly, clinical audits will help in understanding the level of 
care being provided to the patient and minimise the gap between clinical practice and 
guidelines. This on-going process will give valid and important information to health 
care workers that will help them to improve their practice.  
Worldwide, guidelines have been produced to assist health care workers in their quest to 
render proper care but unfortunately the implementation of the standards of care for 
diabetes has been less than optimal in most clinical settings.9 
 Family physicians have the professional responsibility of constantly checking whether 
the standard of care he/she offers is effective, equitable, efficient and humane. There 
may be evidence of the success of certain interventions but if they are not being 




Chapter 3 METHODOLOGY 
1. Introduction 
This chapter will review the study design and setting, the population from which the 
sample was taken, inclusion and exclusion criteria and information about what data was 
collected. This is followed by how the data was analysed and a description of ethical 
approval that was received.   
2. Study Design 
This study used a quantitative, descriptive and retrospective design. It was exploratory 
in nature and assessed whether guidelines were currently being followed. No 
interferences or associations were made. 
3. Study Setting  
The study was carried out at Leratong Hospital, which is a regional level hospital in 
Gauteng province, South Africa. It has a capacity of 900 beds of which 813 are usable. 
Leratong Hospital is a public health facility that provides services to the people living in 
the West Rand District of Gauteng.  For historical reasons, the residential areas are 
largely inhabited by black people, most of whom are unable to afford private medical 
aid.  It is an area characterized by a range of residential houses, ranging from formal 
houses to informal settlements. A community survey in 2007 showed that 51.48% of the 
population around the hospital was male. This may be due to the job opportunities and 
migrant labour which brought men from rural areas to the west rand.18 
Leratong Hospital serves the population of the West Rand with two district hospitals 
and one psychiatric hospital, namely: Dr Yusuf Dadoo, Carletonville and Sterkfontein 
Hospitals. Many clinics and General Practitioners refer their patients to Leratong 
Hospital. 
This site was chosen for convenience as the researcher is an employee at the hospital.  
Poorly controlled diabetic patients are regularly seen at the hospital – often in casualty.  
A diabetic clinic, supervised by the Department of Internal medicine is run every 
Tuesday in the outpatient department and approximately 600 diabetic patients are seen 
9 
 
each month.  Patients are seen at monthly intervals or more frequently if their diabetes 
is poorly controlled. Once patients are stable they are referred back to their local clinic 
for on-going follow up. The diabetic team at Leratong Hospital consists of three 
medical officers, a diabetic nurse and a dietician. Patients who need ophthalmological 
consult are referred to the ophthalmologist in the hospital.  
In 2008 the clinical manager at Leratong hospital introduced the SEMDSA guidelines in 
an attempt to optimise the treatment provided to diabetic patients. As alluded to in the 
literature review, these guidelines outline investigations that should be done to monitor 
for complications and targets that should be reached to reduce the development of 
complications. The researcher has noted that despite these guidelines being introduced, 
there appears to have been little obvious improvement in patient indicators such, as 
glycaemic control.  
4. Study Population 
The study population was all patients with type 2 diabetes who attended the diabetic 
clinic at the hospital during the study period 
5. Study Sample 
The study sample was all patients with type 2 diabetes who attended the diabetic clinic 
at Leratong Hospital from the 1st of January 2009 to the 31st of December 2009. This 
time period has been chosen for convenience. 
Using Epi Info Version 3.2 (C.D.C,2004),with more than 600 type 2 diabetic patients 
attending the clinic per month, the sample size for a cross-sectional study was calculated 







6. Data Source 
The medical records of all patients with Type 2 diabetes during the study period were 
examined and the first 388 patients who met the inclusion criteria constituted the 
sample. This was a convenient sample. However it was assumed that patients present to 
the clinic in a random order and that files in the pharmacy are in a random order. It was 
not anticipated that bias was introduced by the sampling method.  
7. Inclusions and exclusion Criteria 
The inclusion criteria consisted of: 
• Clinic records of patients with type 2 diabetes. 
• Patient who had been treated for type 2 diabetes at the study site for at 
least 12 months prior to this study.  
The exclusion criteria consisted of: 
• Type 1 diabetes mellitus 
• Gestational diabetes 
 
8. Data Collection 
Data from the clinic records was transcribed to an audit tool (Appendix 1). This audit 
tool was based on standards of care established by the SEMDSA Guidelines for 
diagnosis and management of type 2 diabetes mellitus for primary health care- 2009.  
Four categories of data were collected:  
1. Demographic details of patients to understand the study population, 
2. The standard tests that should have been be done on patients either monthly or 
annually 
3. The results of the tests, and 




The following data was collected 
• Demographic data: age, gender and race 
• Care processes: 
o HbA1c (at least bi-annually)  
o weight (each regular visit) 
o  Body Mass Index (annually) 
o blood pressure (each regular visit)  
o lipid profile (annually or more frequent if high risk patient)  
o serum creatinine (annually)  
o micro albumin (annually if no persistent proteinuria in urine dipstick) 
o comprehensive foot examination (annually)  
o dilated eye examination (annually),  
o patient education (ongoing education on  diabetes) 
 
• Metabolic outcome: this data was collected to determine the health status of 
the patients with respect to each variable and to determine whether or not they 
were within the target ranges considered acceptable  
o HbA1C <7%: optimal, 7-8%: acceptable, >8%: poorly controlled. 




o diastolic blood pressure: <80 mmHg: optimal,>80mmHg: poorly 
controlled. 
o total cholesterol: <4.5 mmol/l: optimal. 
o LDL cholesterol: < 2.5 mmol/l: optimal. 
o HDL cholesterol: >1.0 mmol/l (men): optimal,> 1.2 mmol/l (women): 
optimal. 
o Triglyceride < 1.7 mmol/l: optimal. 
• Pharmacological management: these data will indicate what treatment 
options were given to the patients based on their test results 
o Treatment for hyperglycaemia  
o Blood pressure treatment 
o Lipid treatment 
o Antiplatelet agents 
 
9. Data Analysis 
The extent to which the results obtained met the guidelines was assessed to determine 
whether patients received the necessary tests, were optimally controlled, acceptably 
controlled, or poorly controlled as determined by whether or not their results were 
within acceptable limits, and if appropriate treatment strategies were provided. The data 
on the research tool was entered into STATA from where it was exported into excel for 
analysis. 
The data was analysed in the following categories 
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• Demographic data: this was analysed in excel and is presented in a table with 
number and percent by gender, while the ages were graphed.   
• Care processes:  presented in a table with number and percentages.  All the 
variables were analysed independently    
• Metabolic outcome: the patients’ results were aggregated and the descriptive 
analysis of the quantitative variables including mean, median, range and mode, 
while categorical variables were summarized with frequency tables and bar 
charts.  
• Pharmacological management: This data was aggregated by variable and 
analysed for the number and percent of treatments. 
 
10. Ethics 
Approval for conducting this study was obtained from the Biomedical Research Ethics 
Committee of the Nelson R Mandela School of Medicine University of KwaZulu–Natal, 
South Africa (REF: BE 171/010). Permission to conduct the research study was 




Chapter 4 RESULTS 
1. Introduction 
This chapter presents the results of the study and consists of the demographic details, 
care processes, metabolic outcome and pharmacological management.  The 
demographic data of participants consisted of age, sex and race. The care processes 
consisted of  HbA1C, weight, BMI, BP, lipid profile, serum creatinine, micro 
albuminuria, urine dipstick, foot examination, eye examination, and patient education. 
The metabolic outcomes were BP and lipid profile which were ascertained to determine 
whether they were optimally or poorly controlled and whether HbA1C was optimally, 
acceptably or poorly controlled.  The therapeutic approaches were reviewed in relation 
to the recommendation of the SEMDSA guidelines for the management of patients with 
type 2 diabetes. 
2. Demographic Data 
Three hundred eighty eight patients constituted our sample size. Of the 388 patients’ 
records that were obtained, information on gender was missing for 23 patients - see 
table 1 for other important demographic data.   The mean age of the patient was 55.7 
years (SD 10.02), ranging from 33 to 83 years. All patients were African. 
Table 1 Gender of participants 
Gender Number Percent 
Female 171 44.1 
Male 194 50.0 
Missing 23 5.9 
Total 388 100 
 
3. Care Processes 
Some of the care process data was collected monthly and some annually.  However, the 
data was aggregated and a summary of results is presented. 
Patients’ education, blood pressure measurement, urine dipstick and serum creatinine 
were the processes recorded, with more than 90% of these items being recorded in the 
notes. The quality of the health education given to patients was not assessed – which 
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may mean that this was not a very helpful variable to measure. Eye examinations, BMI, 
weight, glycosylated haemoglobin were recorded in 51.8%, 60.31%, 5.67, and 64.95% 
respectively. Comprehensive foot examinations and micro albumin were recorded in 
less than 1% of patients while lipid profile was estimated in 21.39% of patients (Table 
2).  
The low rate of weight measurement compared to BMI measurement is because, 
according to the guideline, weight should be recorded at each visit while the BMI is 
calculated only once a year. This will explain the reason for a high percentage of 
patients having their BMI recorded and a low percentage of patients having their weight 
recorded.  





HbA1C once 99 25.5 
HbA1C twice 153 39.4 
Weight 22 5.7 
BMI 234 60.3 
BP 374 96.4 
Lipid 83 21.4 
Serum creatinine 351 90.5 
Micro albumin 2 0.5 
Urine dipstick 353 91.0 
Foot examination 1 0.3 
Eye examination 201 51.8 
Patients education 381 98.2 
 
4. Metabolic Outcomes 
Metabolic data is presented in table 3. Some data was missing in some folders.  The 
sample mean HbA1C was 8.18 ±1.17%. The mean systolic and diastolic blood pressures 
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were 134.7 ±15.0 and 87.9 ± 9.6 mmHg, respectively. The mean total plasma 
cholesterol concentration was 3.94 ± 0.7 mmol/l. The mean LDL cholesterol level was 
1.99± 055 mmol/l and the mean HDL cholesterol levels were 1.4± 0.3 and 1.7 ± 0.98 
mmol/l in men and women respectively. (Table 3) 
 
Table 3. Metabolic outcomes 
Characteristic number Mean Std. 
Dev* 







least once a 
year 
252 8.2 1.2 6.3 12.8 5.6 40.9 53.6 
SBP 381 135 15.0 103 197 46.7 - 53.3 
DBP 381 88 9.6 57 120 16.8 - 83.2 
Total 
cholesterol 
78 3.9 0.7 1.3 5.4 80.8 - 19.2 
LDL 
cholesterol 








75 1.7 1.0 0.5 6.8 39.5 - 11.8 
Triglyceride 75 1.2 0.4 1 2 74.7 - 25.3 
%Opt.cont: percentage of optimal control, %Accep cont.: percentage of acceptable 
control, %Poor cont: percentage of poor control 
 
Control target of HbA1C: of the 252 patients for whom data was available, only 5.6 % 
(n=14) were optimally controlled, 41 % (n=103) had acceptable control and more than 




Figure 1. Control target of HbA1c 
 
Blood pressure control:  the systolic blood pressure of 53.3% (n=203) was poorly 
controlled which represented more than half of the sample. (Figure2) 
 
Figure 2. Control target of SBP 
 
The diastolic blood pressure of the majority of the patients was poorly controlled, with 
only 16.8% conforming to the SEMDSA guidelines. (Figure 3) 
Optimal Acceptable Poorlycontrolled Total
Number 14 103 135 252












Optimal Poorly controlled Total
Number 178 203 381


















Figure 3. Control target of DBP 
 
Lipid profile: Data for total cholesterol in the previous 12 months was available in only 
78 patients in whom 80% were well controlled. (Figure 4) 
 
Figure 4. Control target of cholesterol 
 
 
 LDL cholesterol control: many patients had data missing for their LDL cholesterol. Of 
the 76 for whom there was data; two thirds (67.11%) were well controlled, with the 
remaining third being poorly controlled. (Figure 5)  
Optimal Poorly controlled Total
Number 64 317 381















Optimal Poorly controlled Total
Number 63 15 78















Figure 5.Control target of LDL cholesterol 
 
HDL cholesterol control: while many patients had missing data for HDL cholesterol 
most of them were well controlled (Figure 6) 
 
Figure 6. Control target of HDL cholesterol 
Abbreviations.  M.opt: male optimal control 
M.PC: male poorly controlled 
F.opt: female optimal control 
F.PC: female poorly controlled 
Optimal Poorly controlled Total
Number 51 25 76












M. opt. M. PC F. opt. F. PC Total
Number 29 8 30 9 76















Data for triglyceride control was found in 75 patients and the majority of them were 
well controlled (Figure 7). 
 
Figure 7. Control target of triglyceride 
 
5. Pharmacological management 
Table 2 summarizes the pharmacological management of patients.   
 
Table 3. Pharmacological management approach 
Medications Number (388) Percent 
Single oral diabetic agent 18 4.6 
Two orals diabetic agents 151 38.9 
Oral diabetic agents and insulin 138 35.6 
Insulin 81 20.9 
Aspirin 357 92.0 
Clopidogrel 2 0.5 
Statin 132 34.0 
Optimal Poorly controlled Total
Number 56 19 75














Fibrate 2 0.52 
ACE (or ARB) 366 94.3 
ACE (or ARB) and HCTZ 351 91 
ACE (or ARB), HCTZ, Loop diuretic.   11 3 
ACE (or ARB), Loop diuretic.  11 3 
 
Blood glucose management: 4% (n=18) of patients were prescribed one oral diabetic 
agent; 39% (n=151) of patients were on two oral diabetic agents; 35% (n=138) were on 
oral diabetic medication and insulin and 21% (n=81) were receiving only insulin 
(Figure 8). Blood pressure management: 94.3% (n=366) of patients were on ACE (or 
ARB), 91% (n=351) of patients were prescribed both ACE (ARB) and HCTZ. 
 
 











Insulin Only Insulin Total
Number 18 151 138 81 388

















Lipid management: only 34% (n=132) of patients were prescribed statin therapy (Figure 
9). It is important to emphasize the importance of statin therapy among diabetic patients 
as high lipids are a major contributor to excess mortality due to the increased risk of 
atherosclerotic vascular disease. 
 
Figure 9. Lipid management 
 
Antiplatelet management: 92% (n=357) were receiving aspirin according to the 
guideline – see Figure 10.  
 
Figure 10. Aspirin uses 
No Yes Total
Number 256 132 388
















Number 31 357 388

















Chapter 5 DISCUSSION 
1. Introduction 
This chapter discusses the results of our study in four sections. Firstly the demographic 
details followed by the care process, thirdly, the metabolic outcomes, and lastly, the 
therapeutic approach. After this the study limitations and recommendations are 
discussed.  
2. Demographics Data 
There were more men in this study than women, with a mean age of 56 years. All the 
patients were black. Although diabetes affects men and women in equal numbers, it is 
unusual for more men than women to be accessing care and for more men to be enrolled 
in the study than women. The study population in a study done by Levitt19in Cape Town 
in 1996 on diabetes and complications associated with diabetes was predominately 
women.Klisiewicz in his study in Johannesburg in 2009 showed that sixty five percent 
were female and thirty five were male while the mean age for the patients was 
59,8%(SD10,77).20   Further study need to be done to determine whether these figures 
reflect greater access by men to services or bias due to sample selection and the 
population served.  
3. Care Processes 
The care processes are activities which should be performed on a regular basis on 
patients who are being managed for type 2 diabetes. The result showed a wide variation 
among doctors regarding performing of the expected physical examination and 
laboratory tests, with some of them done more consistently than others. 
Sixty five percent of patients had at least one reported measure of HbA1c. This figure is 
higher than that reported by Erasmus21 in the Eastern Cape in 1996 and Levitt19in Cape 
Town who found 24% and 3,4% patients respectively had had their HbA1c checked. 
However a study on diabetic care provided in Britain by Tunbridge22 in Newcastle in 
1990 showed that 80 % of patient had at least one reported measure of HbA1c per year. 
A study by Suwattee Pet23 in 2000 in the United States, found that 94% of patients had 
their HbA1c recorded annually. The HbA1c gives an indication of long term diabetic 
care and it is important that health care providers to regularly measure the HbA1c and 
discuss the implications of an abnormal result with patients.  
Only 22% of patients had their weight recorded on each visit, which is much lower than 
that reported by Erasmus21 in his study in the Eastern Cape in 1996 and Levitt19in Cape 
Town in 1996 who found that 100% of patients had their weight recorded.  Sixty 
percent of patients in this study had their BMI calculated which is higher than that 
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found by Goudswaard 21 in his study in Utrecht in 1999 reported that only 29% of 
patients had their BMI recorded while Martell R while Van Vuuren reported that only 
5% of patients had their BMI recorded in their study in Cape Town in 2005.26   It is not 
only in South Africa where important details are not recorded. In 2005 Vinker25 in Israel 
reporting that only 39 % of diabetic patients had their BMI recorded.  Measuring BMI is 
an important care process as BMI is an objective measure and targets can be set and 
patients encouraged to lose weight as necessary.  
The majority of patients (96%) had their BP checked regularly, and the findings of this 
study are comparable to a study by Akel M and Hamadeh10 done in Lebanon in 1999 
which found that 85.8% of patients had their BP documented. Tunbridge22in his study in 
Newcastle in 1990 noted that 87% of patient had their BP recorded on a regular basis.  
These findings are also consistent with the finding of other South African studies. In a 
study in the Western Cape in 2005, Martel R26 showed that 88.5% of patients attending 
the diabetic clinic had their BP checked regularly while Levitt19 in 1996 showed that 
97.5% of diabetic patients had their BPs recorded regularly. This is an important finding 
as poorly controlled BP is a risk factor for cardiovascular disease in diabetic 
patients.13Measuring the BP and responding to abnormal BP results is not the same. 
This study did not however look at whether or not health care providers responded 
appropriately to abnormal BP results. There is a need for further research to look at this 
aspect of the management of hypertension among diabetic patients.  
Despite the guidelines recommending an annual eye examination, eye examination was 
done in just over 50% of patients. Screening for micro vascular complication (micro 
albuminuria and diabetes related foot conditions) was also poorly done. This is 
consistent with the findings of other studies in South Africa and in other parts of the 
world. Levitt et al 19 in their study done to evaluate the quality of health care received 
by diabetic patients in Cape Town in 1996, found that eye and foot examination were 
rarely recorded. Novo A and Jokic 27 in 2007 in Bosnia and Herzegovina found that on 
average only 50% of patients had a foot or eye examination with even less patients 
being screened for micro albuminuria. Foot examination is an important preventive 
measure and should be part of routine care in diabetic patients, as foot disease and 
amputations for gangrene in diabetic patients is not uncommon.  
Blood pressure, urine dipstick and patients’ education were all done well and appear to 
have been systematically incorporated into routine practice. Studies have shown that 
examinations and screening tests that are incorporated into routine care (often done by 
nursing staff) are more likely to be done. In 2007, Ohman-Strickland PA28 assessed 
whether the quality of diabetes care differed among US practices employing nurse-
practitioners, physicians assistants, or neither. They concluded that family practices 
employing nurse-practitioners performed better than those with physicians only and 
those employing physicians assistants, especially with regard to diabetes process 
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measures, as these measurements were more likely to get done in practices employing 
nurse practitioners.  
In South Africa BP measurement, urine dipstix and patient education are within the 
scope of practice of the nurses.  In public hospitals the nurses are responsible for 
recording vital signs, doing urine dipsticks and conducting patient education, all of  
which is usually done on each visit before the consultation.  
4. Metabolic Outcomes 
The mean HbA1c of 8.2 ± 1.17% indicates that the level of glycaemic control in our 
study is suboptimal with only 5.6% (n=14) of patients with HbA1c values which meet 
the SEMDSA guideline target.4 This is much worse that the 47% of patients with 
HbA1c values of less than 7 % which Coon and Zulkowski29 found in 1999 achieved by 
health care providers in the USA. The finding of this study are worse that those found in 
Australia in 2003 where Bryant30found that 30% of patients met the target value of 
HbA1c of less than 7%. These findings are worse than the findings of Levitt19 in Cape 
Town in 1996  who reported 20% of their patients had a normal HbA1c. It is of concern 
that guidelines are not being followed in doing HbA1c and even when the blood is 
taken, the vast majority of patients are not meeting the targets set by the SEMDSA 
guidelines. Health care providers need to ensure that patients adhere to lifestyle changes 
and are compliant with their medication. If adequate control is still not being achieved 
then dosages need to be adjusted or insulin introduced to ensure that patients reach the 
HbA1c targets.  
The mean SBP and DBP in our study were 135  ± 15 and 87.9 ±9.6. Coon and 
Zulkowski in 200229 found mean SBP of 139±18.8 and mean DBP of 75±11.5 
respectively. Fifty three percent and 83 % of patients had SBP and DBP respectively 
above the recommended targets in our study.  However our patients had better 
controlled SBP than DBP compared to the study done by Coon and Zulkowski29where 
only 28% of the patient of the patients had controlled SBP and 79% of the patients had 
controlled DBP.  BP control is often challenging and multiple agents are often required 
to achieve BP targets. 
Of those patients who did have their lipid panel tested, the majority achieved the 
optimal target. The lack of testing for lipids indicates that the doctors are not requesting 
the necessary information which will allow them to make an accurate diagnosis of 
hyperlipidaemia. The doctors are therefore unable to manage abnormal lipids 
appropriately in order to decrease the risk of atherosclerotic vascular disease. 
5. Pharmacological management 
The use of ACE or ARB, HCTZ and aspirin in our study is in accordance with the 
recommendation of the SEMDSA guidelines.4  However, less than 50% of patients in 
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our study were getting lipid-lowering medications. With regard to the recommendation 
of the SEMDSA guidelines, the results suggest a need to increase the number of patients 
on lipids as the mismanagement of dyslipidaemia in patients with type 2 diabetes leads 
to an increased risk of cardiovascular disease. 
6. Limitations 
 As this was a retrospective study it was not possible to deal with each individual 
patient, it is difficult to determine which of their physiological factors contribute to 
what result.  This was an observational descriptive study and the results are presented 
using tables and charts with no statistical testing to determine statistical significance.  
The sampling method may have introduced bias. Missing data in a number of the 








Chapter 6 RECOMMENDATIONS AND CONCLUSIONS 
1. Introduction 
The result of this study indicates that physicians at Leratong Hospital’s diabetes clinic 
are not fully complying with the SEMDSA guidelines for the management of patients 
with type 2 diabetes, which results in the majority of patients not reaching the desired 
outcomes.  Despite evidence that intensive control of cardiovascular risk factors reduces 
morbidity and mortality in patient with type 2 diabetes, this study revealed that a large 
number of patients were not achieving recommended treatment targets. 
2. Recommendations 
The following recommendations are made as a result of this study:  
- Guidelines and protocol for diabetes management and care must be available in 
all consulting rooms for doctors to access. 
- A diabetes flow-sheet needs to be included in  the diabetic medical record of 
each patient to facilitate disease management  
- A quality improvement programme team should be instituted at the hospital and 
should meet regularly  to address matters relating to appropriate diabetes 
management and care 
- Training of health care workers participating in the management of patients with 
type 2 diabetes needs to take place on a regular basis 
- The importance of record keeping needs to be stressed to all health care staff 
involved in patient management not only to ensure optimal care for each person, 
but to enable the clinic performance to be assessed 
- More staff need to be allocated to the clinic due to the high patient load and the 
pressure that this puts the doctors under to see all the patients. Standing orders to 
allow nurses to perform routine tests would help ensure that, by the time patients 
are seen by the doctor,  a number of tests have been done. 
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- Further research is needed to understand the barriers to implement diabetes 
guidelines. A better understanding of such barriers will enable management to 
implement alternative strategies to improve care to diabetic patients. 
 
3.  Conclusion 
The results of this study indicate that the SEMDSA guidelines are only being adhered to 
in part by the staff at Leratong Hospital.  Those duties performed by the nurses are more 
likely to be executed, while the doctors do not always request for tests to be done.  The 
quality of care may be compromised by the high patient load at the clinic and the desire 
by the medical staff to see everyone, resulting in tests being missed in the interest of 
time.  However, the results also show that once tested, patients are not being given the 
treatment they need to effectively manage their disease, which could result in 
unnecessary morbidity and early mortality. The lack of data recorded in the patient’s 
files is of concern as it may not accurately reflect the testing done and care provided.   
This study has also shown that patients are not receiving the optimal levels of care, even 
when tests are done.  As Leratong Hospital has the facilities and capability to provide 
high quality care to its patients, it is important for the medical staff to use the guidelines  
provided and to regularly audit the standard of care provided.    
This study should constitute a baseline for the future research and evaluation of the 
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AUDIT TOOL FOR THE MANAGEMENT OF DIABETIC TYPE 2 





























HbA1c at least 
2 times a year 
            
Weight/Waist 
regular visit 
            





            
Lipid profile at 
least once a 
year 




            
Microalbumin 
measurement 
annually if no 
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Urine dipstick 
at each visit 
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